Astrana Health, Inc. (NASDAQ: ASTH), a prominent healthcare management company, has recently been the subject of analysis by several financial experts. These evaluations provide a comprehensive view of the company's current market position and future prospects.
As of April 1, 2025, Astrana Health's stock is trading at $29.86, reflecting a decrease of approximately 3.84% from the previous close.
The consensus among six financial analysts is a "Moderate Buy" rating for Astrana Health's stock. Price targets set by these analysts vary, with estimates ranging from $49.00 to $70.00. The average 12-month price target is approximately $56.83, suggesting a potential upside of about 90% from the current trading price.
In August 2024, Baird raised its price target for Astrana Health to $67, maintaining an "Outperform" rating. The firm highlighted the company's undervaluation and anticipated significant growth, particularly with the expected full-risk conversion of approximately 1 million members, which could lead to a 24% increase in revenue and a 21% rise in adjusted EBITDA over a three-year compounded annual growth rate.
In March 2025, Bank of America (BofA) adjusted its price target to $49, keeping a "Buy" rating. This adjustment followed mixed fourth-quarter financial results, where the company met EBITDA estimates but fell short on certain cost ratios. Despite this, BofA maintained a positive outlook, citing potential for growth through rate recapture and integration synergies.
Also in March 2025, Truist reaffirmed its "Buy" rating with a price target of $50. The firm expressed confidence in Astrana Health's ability to meet demand within the value-based care industry and highlighted the company's robust top-line growth rate, with revenue increasing by nearly 47% over the last twelve months.
Astrana Health's recent acquisition of Prospect Health System is viewed as a strategic move to enhance its provider network and care delivery capabilities. The acquisition is expected to contribute significantly to the company's revenue and adjusted EBITDA, further strengthening its position in the market.
The evaluations from these six analysts present a cautiously optimistic outlook for Astrana Health. While acknowledging certain challenges, they emphasize the company's growth potential, strategic acquisitions, and strong positioning within the value-based care sector. Investors are advised to consider these insights alongside their individual investment strategies and risk tolerance.